Kazia Therapeutics (KZIA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $7.25, -2.03% vs the prior close of $7.40.
- Volume 273.17K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
KZIA dips 2.0% to $7.25. Closed at $7.25, -2.03% vs the prior close of $7.40. Day range $7.15–$7.79, opened at $7.44.
KZIA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — KZIA dips 2.0% to $7.25
- Closed at $7.25, -2.03% vs the prior close of $7.40. Day range $7.15–$7.79, opened at $7.44.
- Volume was 273.17K shares, 0.9x its 50-day average of 293.72K.
- Price is -36.1% vs its 50-day average ($11.34) and -30.7% vs its 200-day average ($10.46).
- 52-week range $4.86–$17.40; today's close sits at 19% of that range, 58.3% below the 52-week high.
Oct 15, 2026 — KZIA jumps 9.0% to $7.40
- Closed at $7.40, +8.98% vs the prior close of $6.79. Day range $6.80–$7.59, opened at $6.80.
- Volume was 385.70K shares, 1.3x its 50-day average of 290.67K.
- Price is -35.3% vs its 50-day average ($11.44) and -29.2% vs its 200-day average ($10.45).
- 52-week range $4.86–$17.40; today's close sits at 20% of that range, 57.5% below the 52-week high.
Oct 14, 2026 — KZIA slides 15.5% to $6.79, a 6-month low on 3.0x normal volume
- Closed at $6.79, -15.55% vs the prior close of $8.04. Day range $6.62–$8.31, opened at $7.85.
- Volume was 825.30K shares, 3.0x its 50-day average of 277.21K — unusually heavy trading.
- Price is -41.1% vs its 50-day average ($11.54) and -35.0% vs its 200-day average ($10.45).
- 52-week range $4.86–$17.40; today's close sits at 15% of that range, 61.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — KZIA slides 8.7% to $8.04, a 6-month low
- Closed at $8.04, -8.74% vs the prior close of $8.81. Day range $8.00–$8.94, opened at $8.77.
- Volume was 273.80K shares, 1.0x its 50-day average of 275.68K.
- Price is -31.0% vs its 50-day average ($11.65) and -23.1% vs its 200-day average ($10.45).
- 52-week range $4.86–$17.40; today's close sits at 25% of that range, 53.8% below the 52-week high.
Oct 12, 2026 — KZIA dips 1.3% to $8.81, a 6-month low
- Closed at $8.81, -1.34% vs the prior close of $8.93. Day range $8.72–$9.18, opened at $9.05.
- Volume was 66.80K shares, 0.2x its 50-day average of 280.31K — lighter than usual.
- Price is -24.9% vs its 50-day average ($11.73) and -15.7% vs its 200-day average ($10.45).
- 52-week range $4.86–$17.40; today's close sits at 31% of that range, 49.4% below the 52-week high.
Oct 9, 2026 — KZIA rises 1.2% to $8.93
- Closed at $8.93, +1.25% vs the prior close of $8.82. Day range $8.75–$9.08, opened at $8.89.
- Volume was 123.40K shares, 0.4x its 50-day average of 284.42K — lighter than usual.
- Price is -24.4% vs its 50-day average ($11.81) and -14.6% vs its 200-day average ($10.45).
- 52-week range $4.86–$17.40; today's close sits at 32% of that range, 48.7% below the 52-week high.
Oct 8, 2026 — KZIA slides 5.1% to $8.82, a 3-month low
- Closed at $8.82, -5.06% vs the prior close of $9.29. Day range $8.71–$9.51, opened at $9.25.
- Volume was 252.40K shares, 0.9x its 50-day average of 282.61K.
- Price is -25.8% vs its 50-day average ($11.89) and -15.6% vs its 200-day average ($10.46).
- 52-week range $4.86–$17.40; today's close sits at 32% of that range, 49.3% below the 52-week high.
Oct 7, 2026 — KZIA rises 0.3% to $9.29
- Closed at $9.29, +0.32% vs the prior close of $9.26. Day range $9.14–$9.53, opened at $9.20.
- Volume was 133.50K shares, 0.5x its 50-day average of 283.97K — lighter than usual.
- Price is -22.3% vs its 50-day average ($11.95) and -11.2% vs its 200-day average ($10.47).
- 52-week range $4.86–$17.40; today's close sits at 35% of that range, 46.6% below the 52-week high.
Oct 6, 2026 — KZIA dips 1.0% to $9.26, a 3-month low
- Closed at $9.26, -0.96% vs the prior close of $9.35. Day range $9.16–$9.65, opened at $9.53.
- Volume was 129.90K shares, 0.5x its 50-day average of 284.85K — lighter than usual.
- Price is -23.0% vs its 50-day average ($12.02) and -11.6% vs its 200-day average ($10.47).
- 52-week range $4.86–$17.40; today's close sits at 35% of that range, 46.8% below the 52-week high.
Oct 5, 2026 — KZIA rises 0.9% to $9.35
- Closed at $9.35, +0.86% vs the prior close of $9.27. Day range $9.12–$9.54, opened at $9.31.
- Volume was 240.60K shares, 0.8x its 50-day average of 286.40K.
- Price is -22.6% vs its 50-day average ($12.08) and -10.7% vs its 200-day average ($10.47).
- 52-week range $4.86–$17.40; today's close sits at 36% of that range, 46.3% below the 52-week high.
Oct 2, 2026 — KZIA dips 2.1% to $9.27, a 3-month low, 3 down days in a row
- Closed at $9.27, -2.11% vs the prior close of $9.47. Day range $9.12–$9.74, opened at $9.59.
- Volume was 128.70K shares, 0.4x its 50-day average of 291.45K — lighter than usual.
- Price is -23.6% vs its 50-day average ($12.14) and -11.5% vs its 200-day average ($10.47).
- 52-week range $4.86–$17.40; today's close sits at 35% of that range, 46.7% below the 52-week high.
- That makes 3 straight losses.
KZIA latest news & SEC filings
Every SEC filing by or about KZIA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 22, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 22, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 22, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 22, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 22, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 18, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 1, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 1, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 1, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 1, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade KZIA
- How much it moves: over the last 20 sessions the average daily move was 3.66% (largest 15.5%). That is a volatile stock.
- Liquidity: about 273.09K shares (≈$1.98M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $7.25 vs a range of $4.86–$17.40 (19% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:5 on Apr 17, 2025, 1:10 on Oct 28, 2024
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Sep 22, 2026; 6-K Sep 18, 2026; 6-K Sep 1, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
KZIA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.44 | 7.79 | 7.15 | 7.25 | 273.17K |
| Oct 15, 2026 | 6.80 | 7.59 | 6.80 | 7.40 | 385.70K |
| Oct 14, 2026 | 7.85 | 8.31 | 6.62 | 6.79 | 825.30K |
| Oct 13, 2026 | 8.77 | 8.94 | 8.00 | 8.04 | 273.80K |
| Oct 12, 2026 | 9.05 | 9.18 | 8.72 | 8.81 | 66.80K |
| Oct 9, 2026 | 8.89 | 9.08 | 8.75 | 8.93 | 123.40K |
| Oct 8, 2026 | 9.25 | 9.51 | 8.71 | 8.82 | 252.40K |
| Oct 7, 2026 | 9.20 | 9.53 | 9.14 | 9.29 | 133.50K |
| Oct 6, 2026 | 9.53 | 9.65 | 9.16 | 9.26 | 129.90K |
| Oct 5, 2026 | 9.31 | 9.54 | 9.12 | 9.35 | 240.60K |
| Oct 2, 2026 | 9.59 | 9.74 | 9.12 | 9.27 | 128.70K |
| Oct 1, 2026 | 9.56 | 9.69 | 9.37 | 9.47 | 132.20K |
| Sep 30, 2026 | 9.90 | 9.90 | 9.46 | 9.60 | 188.10K |
| Sep 29, 2026 | 9.72 | 9.84 | 9.43 | 9.75 | 176.40K |
| Sep 28, 2026 | 9.44 | 10.26 | 9.33 | 9.60 | 285.50K |
| Sep 25, 2026 | 9.77 | 9.99 | 9.42 | 9.57 | 244.30K |
| Sep 24, 2026 | 9.50 | 9.99 | 9.01 | 9.78 | 561.00K |
| Sep 23, 2026 | 10.95 | 10.95 | 9.23 | 9.60 | 526.50K |
| Sep 22, 2026 | 10.80 | 11.25 | 10.71 | 10.92 | 321.10K |
| Sep 21, 2026 | 10.53 | 10.79 | 10.19 | 10.65 | 193.50K |
About Kazia Therapeutics
Kazia Therapeutics (KZIA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SYDNEY NSW. State of incorporation: Australia. Fiscal year ends June 30. SEC CIK 1075880.
KZIA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert F Apple | Director | Jul 8, 2026 |
| Steven R. S. Coffey | Director | Jul 8, 2026 |
| Ebru Davidson | Director | Jul 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jeffrey Bonacorda | VP, Finance and Controller | Jul 8, 2026 |
| David Cain | Director, CMC | Jul 8, 2026 |
| John E. Ii Friend | Chief Executive Officer | Jul 8, 2026 |
| James E. Levine | Chief Financial Officer | Jun 23, 2026 |
| Sudha Rao | Chief Scientific Officer | Jun 23, 2026 |
| Jeremy Simpson | Program Director | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
KZIA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
KZIA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on KZIA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.